Erasca(ERAS) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Erasca Reports First Quarter 2024 Business Updates and Financial Results Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare- focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 8, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), ...